These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 33561907)

  • 1. Lack of cross-reactivity between anti-A IgG isoagglutinins and anti-SARS-CoV-2 IgG antibodies.
    Franchini M; Moi P; Cortellazzi M; Danese N; Caruso S; Pasolini P; Ferrazzo S; Piccinini S; Dall'Oglio A; Zovetti P; Negri N; Braga D; Pasquali C; Zuliani E; Glingani C
    Clin Chem Lab Med; 2021 Jun; 59(7):e279-e281. PubMed ID: 33561907
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
    Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
    Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
    Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
    Front Immunol; 2021; 12():626609. PubMed ID: 34084161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric evaluation of clinical specificity and sensitivity of SARS-CoV-2 IgG and IgM serology assays.
    Bohn MK; Hall A; Wilson S; Taher J; Sepiashvili L; Adeli K
    Clin Chem Lab Med; 2021 May; 59(6):e235-e237. PubMed ID: 33577725
    [No Abstract]   [Full Text] [Related]  

  • 6. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
    Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
    Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS.
    Buchholtz ML; Arend FM; Eichhorn P; Weigand M; Kleinhempel A; Häusler K; Bruegel M; Holdt LM; Teupser D
    PLoS One; 2021; 16(5):e0251587. PubMed ID: 33984048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
    Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
    Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
    J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.
    Chavarot N; Leruez-Ville M; Scemla A; Burger C; Amrouche L; Rouzaud C; Lebreton X; Martinez F; Sberro-Soussan R; Legendre C; Zuber J; Anglicheau D
    Kidney Int; 2021 Feb; 99(2):486-488. PubMed ID: 33509358
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
    Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
    BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
    Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
    J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.
    James J; Rhodes S; Ross CS; Skinner P; Smith SP; Shipley R; Warren CJ; Goharriz H; McElhinney LM; Temperton N; Wright E; Fooks AR; Clark TW; Brookes SM; Brown IH; Banyard AC
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33924168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Tancevski I; Weiss G; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 May; 59(6):1143-1154. PubMed ID: 33554557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
    Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
    Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.